TransMedics Group (FRA:8T8) Total Liabilities : €549.6 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is TransMedics Group Total Liabilities?

TransMedics Group's Total Liabilities for the quarter that ended in Dec. 2024 was €549.6 Mil.

TransMedics Group's quarterly Total Liabilities declined from Jun. 2024 (€528.31 Mil) to Sep. 2024 (€518.66 Mil) but then increased from Sep. 2024 (€518.66 Mil) to Dec. 2024 (€549.58 Mil).

TransMedics Group's annual Total Liabilities increased from Dec. 2022 (€84.75 Mil) to Dec. 2023 (€521.63 Mil) and increased from Dec. 2023 (€521.63 Mil) to Dec. 2024 (€549.58 Mil).

TransMedics Group Total Liabilities Historical Data

The historical data trend for TransMedics Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Total Liabilities Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

39.57

59.33

84.75

521.63

549.58

TransMedics Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															521.63	519.21	528.31	518.66	549.58

TransMedics Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TransMedics Group's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.217	+	(492.36	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	549.6

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	767.893	-	218.316
	=	549.6

TransMedics Group's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.217	+	(492.36	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	549.6

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	767.893	-	218.316
	=	549.6

TransMedics Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (FRA:8T8) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TMDX:USA TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group Headlines

No Headlines